首页 | 本学科首页   官方微博 | 高级检索  
     


Intracellular cholesterol transporters and modulation of hepatic lipid metabolism: Implications for diabetic dyslipidaemia and steatosis
Authors:Ugo Soffientini  Anna-Maria CaridisSharron Dolan  Annette Graham
Affiliation:Diabetes Research Group, Institute for Applied Health Research and the Department of Life Sciences, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK
Abstract:

Aims/hypotheses

To examine hepatic expression of cholesterol-trafficking proteins, mitochondrial StarD1 and endosomal StarD3, and their relationship with dyslipidaemia and steatosis in Zucker (fa/fa) genetically obese rats, and to explore their functional role in lipid metabolism in rat McArdle RH-7777 hepatoma cells.

Methods

Expression of StarD1 and StarD3 in rat liver and hepatoma samples were determined by Q-PCR and/or immunoblotting; lipid mass by colorimetric assays; radiolabelled precursors were utilised to measure lipid synthesis and secretion, and lipidation of exogenous apolipoprotein A-I.

Results

Hepatic expression of StarD3 protein was repressed by genetic obesity in (fa/fa) Zucker rats, compared with lean (Fa/?) controls, suggesting a link with storage or export of lipids from the liver. Overexpression of StarD1 and StarD3, and knockdown of StarD3, in rat hepatoma cells, revealed differential effects on lipid metabolism. Overexpression of StarD1 increased utilisation of exogenous (preformed) fatty acids for triacylglycerol synthesis and secretion, but impacted minimally on cholesterol homeostasis. By contrast, overexpression of StarD3 increased lipidation of exogenous apoA-I, and facilitated de novo biosynthetic pathways for neutral lipids, potentiating triacylglycerol accumulation but possibly offering protection against lipotoxicity. Finally, StarD3 overexpression altered expression of genes which impact variously on hepatic insulin resistance, inducing Ppargcla, Cyp2e1, Nr1h4, G6pc and Irs1, and repressing expression of Scl2a1, Igfbp1, Casp3 and Serpine 1.

Conclusions/interpretation

Targeting StarD3 may increase circulating levels of HDL and protect the liver against lipotoxicity; loss of hepatic expression of this protein, induced by genetic obesity, may contribute to the pathogenesis of dyslipidaemia and steatosis.
Keywords:ABCA1, ATP binding cassette transporter A1   Actb, beta-actin   ApoA-I, apolipoprotein A-I   B2m, beta-2 microglobulin   Cyp2E1, cytochrome P450 2E1   FXR, farnesoid X receptor   Gapdh, glyceraldehyde-3-phosphate dehydrogenase   GLUT1, glucose transporter 1   HDL, high density lipoprotein   Hprt1, hypoxanthine phosphoribosyltransferase 1   Igfbp, insulin growth factor binding protein   Irs1, insulin receptor substrate 1   LdhA, lactate dehydrogenase A   LDL, low density lipoprotein   MENTAL, MLN64 N-terminal   MLN64, metastatic liver node 64 StarD3   NAFLD, non-alcoholic fatty liver disease   nash, non-alcoholic steatohepatitis   PGC-1α, peroxisome proliferator activated receptor gamma coactivator 1-alpha   Rplp1, ribosomal protein, large, P1   Srebp, sterol regulatory element binding protein   StAR, steroidogenic acute regulatory protein (StarD1)   StarD, steroidogenic acute regulatory protein (StAR)-related domain   VLDL, very low density lipoprotein
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号